Year All202620252024202320222021202020192018201720162015201420122011 Dec 16, 2022 Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis Nov 22, 2022 Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference Nov 16, 2022 Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis Nov 16, 2022 Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis Nov 4, 2022 National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels Nov 3, 2022 Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights Nov 3, 2022 Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dial Nov 2, 2022 Ardelyx, Inc. Reports Employment Inducement Grants Oct 31, 2022 Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan Oct 27, 2022 Ardelyx to Report Third Quarter 2022 Financial Results on November 3, 2022